Scribd Logo
Upload

Welcome to Scribd!

  • Medical Management of Diabetic Retinopathy: Fenofibrate and ACCORD Eye Studies

    Uploaded by

    apoapoajo
    7 views1 page
    This document summarizes two studies on the medical management of diabetic retinopathy: the FIELD and ACCORD Eye studies. The FIELD study found that fenofibrate reduced the need for laser therapy and prevented disease progression in patients with pre-existing retinopathy. The ACCORD Eye study found that fenofibrate with simvastatin resulted in a 40% lower odds of retinopathy progression over 4 years compared to simvastatin alone, associated with increased HDL and decreased triglycerides. The authors believe fenofibrate is effective for preventing progression of established retinopathy in type 2 diabetes, especially for those with macular edema requiring laser treatment.

    Original Description:

    Original Title

    Clinical Study 4

    Copyright

    © Attribution Non-Commercial (BY-NC)

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document summarizes two studies on the medical management of diabetic retinopathy: the FIELD and ACCORD Eye studies. The FIELD study found that fenofibrate reduced the need for laser therapy and prevented disease progression in patients with pre-existing retinopathy. The ACCORD Eye study found that fenofibrate with simvastatin resulted in a 40% lower odds of retinopathy progression over 4 years compared to simvastatin alone, associated with increased HDL and decreased triglycerides. The authors believe fenofibrate is effective for preventing progression of established retinopathy in type 2 diabetes, especially for those with macular edema requiring laser treatment.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    7 views1 page

    Medical Management of Diabetic Retinopathy: Fenofibrate and ACCORD Eye Studies

    Uploaded by

    apoapoajo
    This document summarizes two studies on the medical management of diabetic retinopathy: the FIELD and ACCORD Eye studies. The FIELD study found that fenofibrate reduced the need for laser therapy and prevented disease progression in patients with pre-existing retinopathy. The ACCORD Eye study found that fenofibrate with simvastatin resulted in a 40% lower odds of retinopathy progression over 4 years compared to simvastatin alone, associated with increased HDL and decreased triglycerides. The authors believe fenofibrate is effective for preventing progression of established retinopathy in type 2 diabetes, especially for those with macular edema requiring laser treatment.

    Copyright:

    Attribution Non-Commercial (BY-NC)
    Download as DOCX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 1

    Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies

    A D Wright1 and P M Dodson1


    1

    Departments of Medical Ophthalmology and Diabetes Birmingham Heartlands Hospital,and Health and Life Sciences, Aston University, Birmingham, UK Correspondence: AD Wright, Departments of Medical Ophthalmology, Birmingham Heartlands Hospital, Aston University, Bordesley Green East, Birmingham, West Midlands, B9 5SS, UK. Tel: +44 (0)121 424 3049; Fax: +44 (0)192 265 6742. Email: A.Wright.1@bham.ac.uk Received 14 February 2011; Accepted 14 February 2011; Published online 25 March 2011. Topof page

    Abstract
    The approach of all ophthalmologists, diabetologists and general practitioners seeing patients with diabetic retinopathy should be that good control of blood glucose, blood pressure and plasma lipids are all essential components of modern medical management. The more recent data on the use of fenofibrate in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye studies is reviewed. In FIELD, fenofibrate (200mg/day) reduced the requirements for laser therapy and prevented disease progression in patients with pre-existing diabetic retinopathy. In ACCORD Eye, fenofibrate (160mg daily) with simvastatin resulted in a 40% reduction in the odds of retinopathy progressing over 4 years, compared with simvastatin alone. This occurred with an increase in HDL-cholesterol and a decrease in the serum triglyceride level in the fenofibrate group, as compared with the placebo group, and was independent of glycaemic control. We believe fenofibrate is effective in preventing progression of established diabetic retinopathy in type 2 diabetes and should be considered for patients with preproliferative diabetic retinopathy and/or diabetic maculopathy, particularly in those with macular oedema requiring laser.
    Keywords: diabetes; retinopathy; fenofibrate

    You might also like